MaxCyte (NASDAQ:MXCT – Get Free Report) is one of 109 publicly-traded companies in the “Life Sciences Tools & Services” industry, but how does it compare to its peers? We will compare MaxCyte to similar companies based on the strength of its valuation, institutional ownership, profitability, dividends, earnings, risk and analyst recommendations.
Risk & Volatility
MaxCyte has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, MaxCyte’s peers have a beta of 0.94, indicating that their average stock price is 6% less volatile than the S&P 500.
Insider & Institutional Ownership
68.8% of MaxCyte shares are held by institutional investors. Comparatively, 53.7% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 4.1% of MaxCyte shares are held by company insiders. Comparatively, 15.0% of shares of all “Life Sciences Tools & Services” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares MaxCyte and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MaxCyte | -114.77% | -18.92% | -16.14% |
| MaxCyte Competitors | -540.60% | -166.50% | -13.58% |
Earnings & Valuation
This table compares MaxCyte and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| MaxCyte | $33.03 million | -$44.63 million | -4.05 |
| MaxCyte Competitors | $2.28 billion | $55.88 billion | -13.70 |
MaxCyte’s peers have higher revenue and earnings than MaxCyte. MaxCyte is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
This is a summary of recent recommendations for MaxCyte and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MaxCyte | 1 | 1 | 1 | 0 | 2.00 |
| MaxCyte Competitors | 948 | 3168 | 5486 | 178 | 2.50 |
MaxCyte presently has a consensus price target of $5.00, suggesting a potential upside of 274.53%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 2.03%. Given MaxCyte’s higher possible upside, research analysts plainly believe MaxCyte is more favorable than its peers.
Summary
MaxCyte peers beat MaxCyte on 7 of the 13 factors compared.
MaxCyte Company Profile
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
